ArticleBlood cancer journal2023

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.

Charalampos Charalampous et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.